Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-9.35 Insider Own0.30% Shs Outstand393.64M Perf Week-2.08%
Market Cap117.94B Forward P/E13.96 EPS next Y21.46 Insider Trans- Shs Float392.56M Perf Month-9.48%
Income-2623.60M PEG- EPS next Q4.42 Inst Own88.10% Short Float1.21% Perf Quarter-1.24%
Sales17.73B P/S6.65 EPS this Y-40.80% Inst Trans-2.77% Short Ratio2.11 Perf Half Y1.32%
Book/sh171.01 P/B1.75 EPS next Y20.21% ROA-2.70% Target Price375.71 Perf Year31.09%
Cash/sh3.88 P/C77.27 EPS next 5Y16.00% ROE-5.50% 52W Range208.64 - 340.34 Perf YTD16.39%
Dividend0.20 P/FCF43.35 EPS past 5Y-42.20% ROI-2.70% 52W High-11.97% Beta0.45
Dividend %0.07% Quick Ratio1.00 Sales past 5Y36.10% Gross Margin57.40% 52W Low43.60% ATR10.46
Employees21600 Current Ratio1.40 Sales Q/Q8.10% Oper. Margin-10.10% RSI (14)43.16 Volatility3.21% 3.44%
OptionableYes Debt/Eq0.64 EPS Q/Q-229.00% Profit Margin-14.80% Rel Volume1.03 Prev Close294.21
ShortableNo LT Debt/Eq0.62 EarningsAug 06 BMO Payout- Avg Volume2.25M Price299.61
Recom1.70 SMA20-3.90% SMA50-4.68% SMA2002.55% Volume2,296,800 Change1.84%
Aug-07-15Reiterated RBC Capital Mkts Outperform $361 → $375
Aug-07-15Reiterated Deutsche Bank Buy $346 → $350
Aug-03-15Resumed JP Morgan Overweight $375 → $400
Jul-28-15Reiterated Leerink Partners Outperform $354 → $388
Jul-28-15Reiterated Canaccord Genuity Buy $352 → $396
Jul-17-15Downgrade RBC Capital Mkts Top Pick → Outperform $361
Sep-03-15 08:02AM  The Next Blockbusters Could Be Balms For Aging Eyes at Investor's Business Daily
Sep-02-15 09:56PM  Ackman's Pershing Square hedge fund drops 9.2 percent in Aug
12:39PM  Investment-Grade Bond Yields Rise, Rate Hike Still in the Cards
07:15AM  Allergan Announces FDA Approval of Updated Label for TEFLARO® (ceftaroline fosamil) PR Newswire
07:03AM  Positive Phase III Results Demonstrate Efficacy Of Antibiotic Medicine AVYCAZ (ceftazidime-avibactam) In Complicated Urinary Tract Infections PR Newswire
Sep-01-15 04:20PM  Allergan Buys Naurex, Boosts Mental Health Portfolio
01:24PM  Hedge Funds Amass Substantial Positions in These Mega-Caps at Insider Monkey
Aug-31-15 02:51PM  Oppenheimer's 10 Stocks to 'Buy on Weakness' at TheStreet
08:00AM  Allergan Successfully Completes Naurex Acquisition PR Newswire
Aug-30-15 07:36AM  We Believe Healthcare's Next Biotech Buyout Target Is at Motley Fool
Aug-29-15 08:02AM  4 IBD 50 Drugmakers Getting Lift From New Treatments at Investor's Business Daily
Aug-28-15 04:34PM  Apple, Amazon Among 27 'Quality' Buys On Dip: Analyst at Investor's Business Daily
10:35AM  Will Clinical Trial Firm Icon Pass This Market Test?
10:35AM  Mylan Shareholders Back Hostile Bid For Perrigo at Investor's Business Daily
08:34AM  Mylan shareholders approve pursuit of Perrigo
Aug-27-15 04:23PM  Expect Perrigo To Grow, With Or Without Hostile Mylan at Investor's Business Daily
04:09PM  What Factors Moved Investment-Grade Bond Yields Last Week?
12:53PM  Here's Why Bill Ackman Isn't Fretting Over The August Stock Market Correction at Forbes
08:30AM  This Former Market Leader Is In Danger Of A Big Plunge
07:45AM  Allergan's Stock Chart Is Flashing a Buy Signal at TheStreet
Aug-26-15 07:00AM  High-Quality Stocks on Sale at Morningstar +5.28%
Aug-25-15 03:06PM  Gilead Leads 4 Drugmakers In Top Sector Performers at Investor's Business Daily
08:46AM  'Bottom fishing' market selloff: Pro
Aug-24-15 09:43AM  Allergan Recalls Eye Treatments Amid Safety Concerns at The Wall Street Journal
Aug-21-15 01:15PM  Why Medivation is a Stunning Biotech Opportunity
11:54AM  Raptor Pharma Stock Up After Cystic Fibrosis Deal at Investor's Business Daily
06:40AM  Here's What Bill Ackman Has Been Buying and Selling at Motley Fool
Aug-20-15 03:24PM  Valeant bets on pink pill
12:45PM  Hedge Fund Stockpickers See U.S. Consumer As The Best Bet In A Rocky Market at Forbes
12:32PM  Allergan, Apple Hedge Fund Favorites; Disney Shorted at Investor's Business Daily
09:30AM  Billionaire Paulsons Top Healthcare Picks Include Allergan PLC (AGN), Valeant Pharmaceuticals Intl Inc (VRX) & Shire PLC (ADR) (SHPG) at Insider Monkey
08:13AM  U.S. FDA Accepts BOTOX® (onabotulinumtoxinA) Resubmission for the Treatment of Lower Limb Spasticity in Adults PR Newswire
06:03AM  Valeant to buy female libido drugmaker for $1B at CNBC
Aug-19-15 04:16PM  Who Could Be Allergan Next Acquisition Target?
02:09PM  Economic Indicators Move Investment-Grade Bond Yields
12:48PM  Infographic: Buffett's Biggest Deal And The Bull Market In Buying Companies at Forbes
08:48AM  13F Recap: The Most Popular (And Unpopular) Stocks Of Q2
Aug-18-15 03:51PM  A Look At Bill Ackman's Super-Concentrated Equity Portfolio
03:11PM  John Paulson Betting On Healthcare And Consumer Discretionary Stocks
Aug-17-15 11:51AM  Who Should Allergan Buy? at
09:35AM  Allergan & Apple Remain Most Popuar Picks Among Hedge Funds but Facebook Gains Ground at Insider Monkey
Aug-14-15 02:22PM  Robertson buys LL stake
11:39AM  Generic-Drug Firms That May Be Swallowed Up at
Aug-13-15 03:53PM  Some Positives Among The Carnage
01:04PM  ALLERGAN PLC Financials
07:40AM  Mylan pursues Perrigo with lower shareholder support for takeover
Aug-12-15 04:15PM  Top protection plays in rocky US markets at CNBC
02:06PM  Protection plays for uncertain times
Aug-11-15 04:05PM  Allergan Confirms Generic Noxafil® Patent Challenge PR Newswire
01:17PM  Cramer's Top Buys to Avoid Currency Issues in China at TheStreet
10:35AM  UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio at 24/7 Wall St.
Aug-10-15 04:05PM  Allergan Successfully Completes Oculeve Acquisition PR Newswire
03:23PM  Rail-Splitters Top New Picks For Q3 at Insider Monkey
Aug-07-15 05:16PM  Cramer confronts CEO on stock drop
09:42AM  Market action on July's jobs report
06:00AM  Jim Cramer's Top Takeaways: Allergan, Disney, Clorox, Zoetis at TheStreet
Aug-06-15 08:12PM  Jim Cramer's 'Mad Money' Recap: This Stock Market Is No Bargain at TheStreet -5.10%
07:13PM  Cramer Remix: It's the slayer of all things media at CNBC
06:24PM  Allergan CEO: More bold acquisitions are possible at CNBC
06:15PM  Allergan CEO: Bold is our tagline
05:45PM  Stock Market Today - 08/06/15
05:41PM  Allergan CEO says better to leave discoveries to others
05:23PM  Allergan Q2 Beats, But Generics Sale Clouds Outlook at Investor's Business Daily
05:21PM  Allergan Swings to Loss on Deals-Related Charges at The Wall Street Journal
04:17PM  Allergan gets DoJ subpoena over generic drug pricing Reuters
02:25PM  Allergan Beats Earnings, Delays Forecast Until Next Quarter at TheStreet
01:55PM  Ironwood's Q2 Loss Wider than Expected, Revenues Miss - Analyst Blog
01:13PM  Allergan's (AGN) 2Q Earnings & Revenues Shoot Up Y/Y - Analyst Blog
12:28PM  Allergan reports 2Q loss due to recent deals
12:26PM  Allergan Brought Into Widening U.S. Probe of Generic Drug Prices at Bloomberg
12:01PM  This Move Caused Teva Pharmaceutical to Catapult Higher By 17% in July at Motley Fool
11:01AM  The Ackman Effect on Stocks: A Brief Look Back at The Wall Street Journal
10:53AM  Allergan says more acquisitions to come at Financial Times
09:51AM  Allergan reports 2Q loss
09:33AM  Allergan reports better-than-expected revenue Reuters
09:30AM  Allergan, it's not whether it's when: Faber
08:59AM  Allergan's (AGN) Q2 Earnings In-Line with Expectations - Tale of the Tape
07:54AM  Actavis reports 2Q loss
07:19AM  Allergan Second-Quarter Profit Surges on Botox, Namenda at Bloomberg
07:11AM  Drugmaker Allergan's revenue more than doubles Reuters
07:07AM  Q2 2015 Allergan PLC Earnings Release - Before Market Open
07:00AM  Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to $5.76 Billion and 29% Growth in Non-GAAP EPS to $4.41 PR Newswire
12:14AM  Business Watch at The Wall Street Journal
Aug-05-15 08:40PM  Business Watch: News Digest at The Wall Street Journal
08:15PM  What to Watch Thursday -- Trump, Bush, Allergan Earnings, Jobless Claims at TheStreet
04:26PM  FDA Approves 28 Additional Styles Of Allergan's Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants PR Newswire
03:59PM  Allergan (AGN) Stock Climbs Ahead of Second Quarter Results at TheStreet
03:43PM  Street Gets More Bullish On Allergan As It Sees Solid Growth Ahead at Forbes
03:02PM  What to Watch in the Day Ahead - Thursday, Aug. 6 Reuters
02:55PM  The Quiet Shareholder Activist? Dan Loeb Seeks Baxter Board Seats Without Fiery Contest at Forbes
02:50PM  Jim Cramer Is Watching Allergan's Earnings After Generics Sale to Teva at TheStreet
02:05PM  What to Expect From Allergan Earnings
12:52PM  Sucampo Stock Hits High On EPS, But CVS Nixes Drug at Investor's Business Daily
11:29AM  Allergan Earnings Are On Deck: Here's Why They Should Meet Expectations
09:06AM  Risks in the TevaAllergan Deal
08:49AM  Allergan Changes Deal for Kythera at The Wall Street Journal
08:00AM  Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration PR Newswire
08:00AM  Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration GlobeNewswire
07:15AM  Allergans $560M Acquisition Suggests VistaGen Could See 330 Percent In Upside
05:00AM  Tevas Just the Start as More Generic Drugmakers Poised to Merge at Bloomberg
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician's offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PYOTT DAVID E IChairman of the Board and CEOFeb 20Option Exercise0.001,3790166,379Feb 24 09:52 PM
Gangolli Julian SCVP & Pres, North AmericaFeb 20Option Exercise0.0051402,418Feb 24 09:44 PM